Excerpts

For example, some of the variants and genes from previous NPC studies were present in our cohorts but failed to reach statistical significance ( p < 0.05), perhaps due to an insufficient sample size.

An absence of primary osteosarcoma metastases was of borderline significance for both overall ( p = 0.050) and event-free ( p = 0.063) survival. 4.

In total, 18 (CRNN, DDX3X/DDX3Y/DDX4, DESP, DHB4, DSG3, ELAF, GBP6, K1C14, K1C16, K2C1, LEG7, PKP1, PKP3, PLAK, SPR1A, SPR1B, SPR2A, and TGM1, Figure 2 ) of these 207 proteins were found to have nominally significant ( p < 0.05, Wilcoxon ranked sum test) differences in abundance levels between cases and controls.

The only difference between age groups was a slightly significant increase of grade ≥3 AE (28% vs. 39%, p < 0.05) for the oldest group (mainly skin reactions, treatment secondary malignancies and renal and urinary disorders).

Patients who had not received (β = 1.05) or who completed RT (β = 1.08), showed a better SumSc score compared to those who were receiving RT, but with a borderline significance ( p = 0.05) ( Table 5 ). 4.

Overall treatment time (OTT) ≥45 days showed a trend for a lower PFS ( p = 0.050) and was significantly associated with lower EFS ( p = 0.030) and histological grade 3 with a lower LC ( p = 0.025).

In the final month, the difference in chemotherapy use is borderline significant (8.5% in males and 6.6% in females; p = 0.05). 3.4.

On the contrary, NB-hop was not able to significantly stratify patients who died, even though we observed a positive trend (OS: p > 0.05, Figure 5 C).

The interaction between tobacco consumption and GDM was non-significant ( p = 0.60) but the interaction between age and GDM was marginally significant ( p = 0.05).

Statistical results were considered significant (*) or highly significant (**) at p < 0.05 and p < 0.01, respectively. 3.

nucleatum ( p = 0.0026), with a trend towards significance for total cultivable bacterial count ( p = 0.0502).

Additionally, nearly significant differences ( p = 0.0503) were seen in the probability of the age of tumor onset between PALB2 P/LP carriers and patients with normal genotypes.

The pooled analysis showed a trend toward improved OS with chemo-immunotherapy (pooled HR 0.78, 95% CI 0.61–1.00; p = 0.0505), although the result missed conventional statistical significance and moderate heterogeneity was observed (I 2 = 50.2%) ( Supplementary Table S1 ).

For example, patients with musculoskeletal irAEs showed a trend towards an improved median PFS of 12 months (95% CI: 5-NA) compared to 5 months (95% CI: 4–8) ( p = 0.0505) in patients with any other irAE and a statistically significant higher PFS compared to patients without irAE (2 months, 95% CI: 1–8) ( p = 0.0068).

We observed that G9a protein expression levels showed a trend of correlating with cirrhosis ( p = 0.0507), but with no other clinical characteristics in our recruited HCC cohort.

When TMB score was added to the adjusted variables above, the 2tPD-L1 more accurately could predict survival; however, this, too, did not quite reach significance ( p = 0.051) ( Table 4 ). 3.6.

While no statistically significant differences were identified between arms, p -values for time-by-arm interactions approached significance (e.g., p = 0.051). 3.7.

Furthermore, in the multivariate analysis it was shown, that tumor stage was the main predictor for DFS and SPARC expression just failed significance with p = 0.051.

Although the median time from first-cycle LDT to first-cycle follow-up imaging approached significance ( p = 0.051), and the greatest impact on TTP was HCC imaging delay.

Despite ICOSLG, only being higher expressed in patients with an above-median PFS at T 0 , there was a trend towards patients with above-median PFS rates having higher levels of ICOSLG at T 2 , which was on the threshold of significance ( p = 0.051), while no trend was observed at T 1 ( p = 0.29). 3.3.

A near-significant relationship was identified between DR type and tumor differentiation grade (χ 2 = 9.448, p = 0.051), with mature stroma most common in Grade 1 tumors, keloid-like stroma in Grade 2, and myxoid stroma in Grade 3.

The 3-year DFS was 91.7% in the alectinib group and 60.7% in the ChT group, albeit with a borderline significant benefit in DFS (HR: 0.17, 95% CI 0.02–1.28, p = 0.051), most likely due to the small sample size.

When stratified by cell-of-origin, the association between rs822336 and RFS was borderline significant in ABC-DLBCL (Kaplan–Meier, p = 0.051), whereas no association was observed in the GCB subtype ( p = 0.300).

Consistently, the recessive model approached but did not reach significance (OR = 1.606, p = 0.051).

PRS was shorter in the LI group regardless of the recurrence risk, although the p -values were marginally significant (LR, 34.04 ± 25.12 vs. 41.62 ± 21.95, p = 0.051; HR, 26.50 ± 22.48 vs. 32.42 ± 22.64, p = 0.033).